Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 5, 2003, Pages 1672-1680

  Karlowsky, James A ^a   Jones, Mark E ^b   Thornsberry, Clyde ^c   Friedland, Ian R ^d   Sahm, Daniel F ^a  

^a Focus Technologies Incorporated   (United States)

^b Focus Technologies   (Netherlands)

^c Focus Technologies   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; ENTEROBACTER CLOACAE; ENTEROBACTER INFECTION; ENTEROBACTERIACEAE; ESCHERICHIA COLI; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEUS MIRABILIS; SPECIES DIFFERENCE; UNITED STATES;

AMPICILLIN; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; SULBACTAM; TIME FACTORS; UNITED STATES;

EID: 0038673433     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.5.1672-1680.2003     Document Type: Article

References (25)

1. Acar, J. F., and F. W. Goldstein. 1998. Consequences of increasing resistance to antimicrobial agents. Clin. Infect. Dis. 27(Suppl. 1):S125-S130.
2. Blumberg, H. M., D. Rimland, D. J. Carroll, P. Terry, and I. K. Wachsmuth. 1991. Rapid development of ciprofloxacin resistance in methicillin-susceptible and -resistant Staphylococcus aureus. J. Infect. Dis. 163:1279-1285.
3. Bradford, P. A. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951.
4. Bush, K., G. A. Jacoby, and A. A. Medeiros. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
5. Cosgrove, S. E., K. S. Kaye, G. M. Eliopoulos, and Y. Carmeli. 2002. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch. Intern. Med. 162:185-190.
6. Eisenstein, B. I., and D. F. Zaleznik. 2000. Enterobacteriaceae, p. 2294-2310. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Philadelphia, Pa.
7. Fridkin, S. K., H. A. Hill, N. V. Volkova, J. R. Edwards, R. M. Lawton, R. P. Gaynes, J. E. McGowan, Jr., and the Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project Hospitals. 2002. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg. Infect. Dis. 8:697-701.
8. Friedrich, L. V., R. L. White, and J. A. Bosso. 1999. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin. Infect. Dis. 28:1017-1024.
9. Hadziyannis, E., M. Touhy, L. Thomas, G. W. Procop, J. A. Washington, and G. S. Hall. 2000. Screening and confirmatory testing for extended spectrum β-lactamases (ESBL) in Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca clinical isolates. Diagn. Microbiol. Infect. Dis. 36:113-117.
10. Hooper, D. C. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341.
11. Jacobson, K., K. Rolston, L. Elting, B. LeBlanc, E. Whimby, and D. H. Ho. 1999. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 45:325-334.
12. Leverstein-van Hall, M. A., A. T. A. Box, H. E. M. Blok, A. Paauw, A. C. Fluit, and J. Verhouf. 2002. Evidence of extensive interspecies transfer of integron-mediated antimicrobial resistance genes among multidrug-resistant Enterobacteriaceae in a clinical setting. J. Infect. Dis. 186:49-56.
13. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
14. Livermore, D. M., D. James, M. Reacher, C. Graham, T. Nichols, P. Stephens, A. P. Johnson, and R. C. George. 2002. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg. Infect. Dis. 8:473-478.
15. Lucet, J. C., S. Chevret, D. Decre, D. Vaniak, A. Macrez, J. P. Bedos, M. Wolff, and B. Regnier. 1996. Outbreak of multiply resistant Enterobacteriaceae in an intensive care unit: epidemiology and risk factors for acquisition. Clin. Infect. Dis. 22:430-436.
16. Meyer, K. S., C. Urban, J. A. Eagan, B. J. Berger, and J. J. Rahal. 1993. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann. Intern. Med. 119:353-358.
17. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing; 11th informational supplement. Vol. 21, no. 1. M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
18. Pena, C., J. M. Albareda, R. Pallares, M. Pujol, F. Tubua, and J. Ariza. 1995. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob. Agents Chemother. 39:520-524.
19. Rello, J., M. Gallego, D. Mariscal, R. Sonora, and J. Valles. 1997. The value of routine microbial investigation in ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 156:196-200.
20. Rice, L. B., S. H. Willey, G. A. Papanicolaou, A. A. Medeiros, G. M. Eliopoulos, R. C. Moellering, and G. A. Jacoby. 1990. Outbreak of ceftazidime resistance caused by extended-spectrum β-lactamases at a Massachusetts chronic-care facility. Antimicrob. Agents Chemother. 34:2193-2199.
21. Richard, P., M. H. Delangle, F. Raffi, E. Espaze, and H. Richet. 2001. Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant Gram-negative bacilli from gastrointestinal flora. Clin. Infect. Dis. 32:162-166.
22. Sahm, D. F., I. A. Critchley, L. J. Kelly, J. A. Karlowsky, D. C. Mayfield, C. Thornsberry, Y. R. Mauriz, and J. Kahn. 2001. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob. Agents Chemother. 45:267-274.
23. Sahm, D. F., M. K. Marsilio, and G. Piazza. 1999. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the surveillance network database - USA. Clin. Infect. Dis. 29:259-263.
24. Shungu, D. L., S. Ponticas, and C. J. Gill. 1989. Comparative activity of cefoxitin, ampicillin/sulbactam, and imipenem against clinical isolates of Escherichia coli and Klebsielia pneumoniae. Clin. Ther. 11:315-318.
25. Weiner, J., J. P. Quinn, P. A. Bradford, R. V. Goering, C. Nathan, K. Bush, and R. A. Weinstein. 1999. Multiple antibiotic-resistant Klebsiella pneumoniae and Escherichia coli in nursing homes. JAMA 281:517-523.